APA (7th ed.) Citation

Y, M., S, B., R, T., C, H., N, K., B, R., . . . TF, G. (2025). Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab. Gut, 74(6), 983. https://doi.org/10.1136/gutjnl-2024-334026

Chicago Style (17th ed.) Citation

Y, Myojin, et al. "Multiomics Analysis of Immune Correlatives in Hepatocellular Carcinoma Patients Treated with Tremelimumab Plus Durvalumab." Gut 74, no. 6 (2025): 983. https://doi.org/10.1136/gutjnl-2024-334026.

MLA (9th ed.) Citation

Y, Myojin, et al. "Multiomics Analysis of Immune Correlatives in Hepatocellular Carcinoma Patients Treated with Tremelimumab Plus Durvalumab." Gut, vol. 74, no. 6, 2025, p. 983, https://doi.org/10.1136/gutjnl-2024-334026.